BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 17338647)

  • 21. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy for low-grade lymphomas: has the time come?
    Cartron G; Solal-Céligny P
    Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
    Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
    Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
    Reiter A; Klapper W
    Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab and chemotherapy in diffuse large B-cell lymphoma.
    Sonet A; Bosly A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):719-26. PubMed ID: 19496708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progress in therapeutic strategy for malignant lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel treatment strategies in follicular lymphoma.
    Buske C; Dreyling H; Unterhalt M; Hiddemann W
    Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
    Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
    Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
    Kosits C; Callaghan M
    Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.